EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Regeneron Pharmaceuticals, Inc (REGN34) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Regeneron Pharmaceuticals, Inc BRL 41.84, price BRL 63.78, upside -34.4%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · ISIN US75886F1075

RP Broad data Sep 29, 2026

Regeneron Pharmaceuticals, Inc

REGN34 · SA

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value R$41.84 · Overvalued (−34.4%)
✓Quality 69/100
✓Healthy Growth (revenue 3y +5.6 %/yr)
✓Highly profitable · 29.7% net margin (TTM)
✓Low debt · generates free cash flow
✓5.6% dividend yield · Well covered
✓Wide moat 72/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$110.97 R$44.99 Fair Value R$41.84 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range R$44.99 – R$110.97 · fair‑value band R$30.22 – R$55.67 · the R$63.78 price screens above the R$41.84 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

Show more

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Stock analysis

Regeneron Pharmaceuticals, Inc (REGN34) currently trades at R$63.78, while our model-based Fair Value estimate is R$41.84, 34.4% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of R$66.34 per share, and 5 of the 25 models we run sit above the R$63.78 price.

Bear case: the Asset-Based group reads lowest at R$17.69, and 20 of the 25 models stay below the price. Evidence for this calculation is high.

Scenario range: R$30.22 (bear) to R$55.67 (bull), the price of R$63.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Regeneron Pharmaceuticals, Inc reported revenue of $14.3B in FY2025 versus $12.2B in FY2022, a compound +5.6%/yr. Reported net income was $4.5B in FY2025, compounding +1.3%/yr from FY2022.

Key figures

Market cap R$365B (≈ $70.0B) · P/E ratio 17.7 · P/S ratio 5.56 · EPS (TTM) R$3.54 · Dividend yield 5.6% · Net margin 31.4% · Return on equity 14.6% · Return on assets (EBIT) 12.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The share trades about 13% below its 52-week high and 27% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −34%, REGN34 screens richer than that median.

Fair Value models

Bear R$30.22 Fair Value R$41.84 Bull R$55.67
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$34.71 R$48.92 R$68.89 77
Growth DCF R$35.78 R$49.15 R$67.21 76
Owner Earnings R$35.33 R$49.80 R$70.14 74
All 25 models by family
DCF Models
FCF DCF R$34.71 R$48.92 R$68.89 77
Owner Earnings R$35.33 R$49.80 R$70.14 74
5Y Revenue Exit R$28.39 R$40.81 R$55.87 70
5Y EBITDA Exit R$33.53 R$49.86 R$67.83 72
5Y P/E Exit R$48.04 R$75.38 R$102.35 68
10Y Revenue Exit R$29.75 R$41.21 R$54.92 65
10Y EBITDA Exit R$33.67 R$47.29 R$63.56 66
10Y P/E Exit R$42.70 R$64.44 R$88.47 61
Earnings-Based
Graham-Dodd R$25.88 R$56.49 R$71.94 63
PEG = 1.0 R$8.90 R$12.71 R$16.53 55
EPV R$23.70 R$27.49 R$30.81 71
Dividend Discount
Gordon GGM R$2.87 R$4.52 R$6.33 65
DDM Multi-Stage R$2.87 R$4.15 R$5.60 64
Multiples
P/E Multiple R$62.80 R$83.73 R$104.66 63
P/S Multiple R$31.81 R$42.41 R$53.01 58
P/B Multiple R$48.53 R$64.70 R$80.88 55
EV/EBIT R$39.50 R$52.34 R$65.19 66
EV/EBITDA R$37.52 R$49.71 R$61.89 67
EV/Revenue R$26.40 R$37.31 R$48.22 54
Asset-Based
NCAV (Graham) R$13.20 R$17.69 R$26.41 54
Growth DCF
Growth DCF R$35.78 R$49.15 R$67.21 76
Rev-Margin DCF R$28.39 R$41.30 R$55.00 70
Economic Profit
Residual Income R$26.05 R$31.81 R$43.10 73
ROIC Compounder R$23.70 R$27.84 R$33.08 69
Growth Earnings
Growth-Adj P/E R$46.44 R$66.34 R$86.24 65

Open the full fair value analysis →

Notify me when REGN34 reaches fair value

Put REGN34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 69/100

Of which business quality 69 · Market factors (momentum, volatility) 63

Profitability 60
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 77
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 71
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 63
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+9.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.0%
Dividend (yield on the price)5.6%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.39% → 25%

REGN34 screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Regeneron Pharmaceuticals, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%
Incyte Corporation INCY $124.82 $201.35 +61%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Regeneron Pharmaceuticals, Inc · Fair Value
R$41.84 −34%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Regeneron Pharmaceuticals, Inc Fair Value". https://www.fairvalue-calculator.com/stock/REGN34

Frequently asked questions

Is Regeneron Pharmaceuticals, Inc (REGN34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$41.84 versus a price of R$63.78, about −34% upside (overvalued).
What is the fair value of REGN34?
Our model-based fair value for Regeneron Pharmaceuticals, Inc is R$41.84 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$63.78.
What is the quality score of REGN34?
Regeneron Pharmaceuticals, Inc has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Regeneron Pharmaceuticals, Inc (REGN34)?
Our model-based price target is the fair value of R$41.84 (as of Sep 29, 2026) from 25 valuation models. Cautious scenario R$30.22, optimistic scenario R$55.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Regeneron Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at R$41.84, about −34% upside versus a price of R$63.78 (overvalued). Cautious scenario R$30.22, optimistic scenario R$55.67. The calculation is refreshed regularly with new filings.
What is the revenue of Regeneron Pharmaceuticals, Inc (REGN34)?
Regeneron Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $14.9B (latest available figure, as of Sep 29, 2026).
Does Regeneron Pharmaceuticals, Inc pay a dividend?
Regeneron Pharmaceuticals, Inc currently shows a dividend yield of about 5.61% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of Regeneron Pharmaceuticals, Inc (REGN34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Regeneron Pharmaceuticals, Inc it is R$41.84 per share (as of Sep 29, 2026), against a price of R$63.78. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Regeneron Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, REGN34 trades above its calculated fair value: price R$63.78, fair value R$41.84, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REGN34?
No. The price is what the market pays today (R$63.78); the fair value is what the company's own numbers justify (R$41.84). For Regeneron Pharmaceuticals, Inc the two are R$21.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Regeneron Pharmaceuticals, Inc worth?
The market values Regeneron Pharmaceuticals, Inc at about R$365B (market capitalisation, as of Sep 29, 2026). Per share that is R$63.78; our models calculate a fair value of R$41.84 per share.
What do the bullish and bearish scenarios say about REGN34?
Our models span a range for Regeneron Pharmaceuticals, Inc: cautious scenario R$30.22, base R$41.84, optimistic R$55.67 per share (as of Sep 29, 2026, price R$63.78). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is REGN34 from its 52-week high?
Regeneron Pharmaceuticals, Inc trades at R$63.78, about 13% below its 52-week high of R$72.94 and 27% above the low of R$50.06 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$41.84 is for.
Which stocks are comparable to Regeneron Pharmaceuticals, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, argenx SE, CSL Limited, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Regeneron Pharmaceuticals, Inc stock attractive at the current price?
The data as of Sep 29, 2026: price R$63.78, calculated fair value R$41.84 (−34%), Quality Score 69/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REGN34 calculated?
We run Regeneron Pharmaceuticals, Inc through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$41.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Regeneron Pharmaceuticals, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Regeneron Pharmaceuticals, Inc (REGN34)?
The closing price on Oct 2, 2026 was R$63.78. Our model-based fair value is R$41.84, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Regeneron Pharmaceuticals, Inc right now?
The price sits above even our optimistic bull case (R$55.67). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (R$30.22 to R$55.67) leaves room in how you read the outcome.

Key figures of Regeneron Pharmaceuticals, Inc

How large is the market capitalisation of Regeneron Pharmaceuticals, Inc (REGN34)?
The market capitalisation of Regeneron Pharmaceuticals, Inc is R$365B (≈ $70.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Regeneron Pharmaceuticals, Inc (REGN34)?
The price-to-earnings ratio of Regeneron Pharmaceuticals, Inc is 17.7. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Regeneron Pharmaceuticals, Inc (REGN34)?
The price-to-sales ratio of Regeneron Pharmaceuticals, Inc is 5.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Regeneron Pharmaceuticals, Inc (REGN34)?
Earnings per share at Regeneron Pharmaceuticals, Inc are R$3.54 (price ÷ EPS = P/E 17.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Regeneron Pharmaceuticals, Inc (REGN34)?
The dividend yield of Regeneron Pharmaceuticals, Inc is 5.6% (payout 101%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Regeneron Pharmaceuticals, Inc (REGN34)?
The net margin of Regeneron Pharmaceuticals, Inc is 31.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Regeneron Pharmaceuticals, Inc (REGN34)?
The return on equity (ROE) of Regeneron Pharmaceuticals, Inc is 14.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Regeneron Pharmaceuticals, Inc (REGN34)?
On an EBIT basis the return on assets of Regeneron Pharmaceuticals, Inc is 12.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Regeneron Pharmaceuticals, Inc (REGN34)?
The operating margin of Regeneron Pharmaceuticals, Inc is 20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Regeneron Pharmaceuticals, Inc (REGN34)?
Revenue at Regeneron Pharmaceuticals, Inc is growing +19.0% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Regeneron Pharmaceuticals, Inc (REGN34)?
Earnings per share at Regeneron Pharmaceuticals, Inc are growing −7.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Regeneron Pharmaceuticals, Inc (REGN34) generate?
The free cash flow of Regeneron Pharmaceuticals, Inc is $3.8B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.